Karyopharm announces xpovio® (selinexor) is now available in additional strength tablets

Newton, mass., june 3, 2021 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq:kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that three new strength tablets for xpovio, the company's first-in-class, oral selective inhibitor of nuclear export (sine) medicine, are now commercially available.
KPTI Ratings Summary
KPTI Quant Ranking